Outsourcing analytical development, more than a cost-saving mechanism, has become a strategic lever that shapes data quality, regulatory confidence, and development speed. When aligned correctly, anal...
Read moreA multidisciplinary Clínic-IDIBAPS team, part of the Clínic Barcelona Comprehensive Cancer Centre (4CB), has published phase 2 results of the CAR-T ARI-0001 (varnimcabtagene autoleucel) for treating...
Read moreOryzon Genomics announced today that the first patient has been dosed in an investigator-initiated Phase Ib dose-finding trial evaluating iadademstat, Oryzon’s potent and selective LSD1 inhibitor, i...
Read moreStrategic research collaboration to advance MTx’s recombinant polyclonal IgG technology
Read moreOryzon Genomics, a clinical-stage biopharmaceutical company and global leader in epigenetics, today announced the appointment of Rolando Gutierrez-Esteinou, M.D., as Chief Medical Officer, CNS Program...
Read moreEl camino que recorre un compuesto bioactivo antes de convertirse en un medicamento seguro y eficaz es largo, complejo y altamente regulado. Antes de avanzar a las fases clínicas, todo candidato debe...
Read morePharmacelera, a deep tech company applying Quantum Mechanics and Artificial Intelligence to revolutionize drug discovery based at the Barcelona Science Park (PCB-UB), has closed a €6 million investm...
Read moreOryzon Genomics, a clinical-stage biopharmaceutical company and global leader in epigenetics, announced today that its management will participate at the following upcoming events
Read moreEn este importante evento el LAM561 es el único fármaco que está actualmente en un estadio de investigación tan avanzado como es el final de la fase clínica 3 y que se dirige a primera línea de ...
Read moreThe study will validate the safety of a novel topical ocular administration route for sitagliptin.
Read moreUn ensayo clínico internacional con seguimiento a tres años, cuyos resultados han sido publicados en JAMA Dermatology, aporta nueva evidencia sobre la evolución a largo plazo de pacientes con psori...
Read moreOryzon Genomics ha anunciado hoy que la Agencia Europea del Medicamento ha aprobado su Solicitud de Autorización de Ensayo Clínico para iniciar un ensayo clínico de Fase II de iadademstat, el inhi...
Read more